Related Experiment Video
Updated: Aug 8, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Long-term outcome of interferon-alpha therapy for chronic hepatitis B
1Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Abstract:
Interferon-alpha therapy has a beneficial effect in 30-40% of selected patients with chronic hepatitis B who respond by clearing hepatitis B e antigen (HBeAg) and hepatitis B viral (HBV) DNA from serum. This is usually associated with normalization of serum aminotransferase activities. On long-term follow-up of treated patients, it is apparent that many go on to clear hepatitis B surface antigen (HBsAg) from serum with considerable improvement in liver histopathology. Among patients with clinically apparent chronic HBV infection such as those with decompensated cirrhosis or the nephrotic syndrome, a serologic response is usually followed by slow but steady clinical and biochemical improvement. However, even among patients who have cleared HBsAg from serum, HBV-DNA remains detectable within the liver and may provide a source of reactivation in rare patients in association with immunosuppression.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction